turoctocog alfa pegol

Turoctocog alfa pegol (N8-GP) is a long-acting, site-specific glycoPEGylated recombinant coagulation factor VIII (FVIII) developed by Novo Nordisk for the treatment and prophylaxis of bleeding in patients with hemophilia A. It is a modified version of turoctocog alfa (N8), where a 40-kDa polyethylene glycol (PEG) molecule is covalently attached to the O-glycan in the truncated B-domain of the FVIII molecule. This modification significantly extends the circulatory half-life (approximately 1.6-fold compared to standard FVIII products), allowing for a reduced dosing frequency in prophylactic regimens. The drug works by replacing the deficient or absent FVIII in patients with hemophilia A, thereby restoring the intrinsic pathway of blood coagulation and enabling the formation of thrombin and fibrin clots. It is indicated for routine prophylaxis, on-demand treatment of bleeding episodes, and perioperative management in both adult and pediatric populations.

Brand names

Esperoct

Other names

GlycoPEGylated turoctocog alfa